AINOS INC

Chiang Yao‑Chung’s recent bulk purchase of Ainos shares signals renewed confidence in its AI‑powered medical tech, hinting at potential upside for investors.

Insider buying trend: Chiang Yao‑Chung’s steady Ainos stake growth, buying at discounts amid positive biotech prospects.

Lee Ting‑Chuan’s May 2026 insider sales of 109k Ainos shares at $1.90 raise questions about liquidity amid a 70% weekly rally, but likely reflect routine tax‑planning.

Insightful Ainos insider buying: Chiang Yao‑Chung’s steady 129‑share purchase hints at long‑term confidence and potential valuation upside for this biotech.

TCNT’s recent Ainos share sell‑off signals tactical liquidity, not a red flag—investors should assess Ainos’ volatility and future plans before re‑valuating.